keyword
https://read.qxmd.com/read/38608433/linagliptin-decreased-the-tumor-progression-on-glioblastoma-model
#21
JOURNAL ARTICLE
Shohei Tsuji, Urara Kudo, Ryo Hatakeyama, Kenji Shoda, Shinsuke Nakamura, Masamitsu Shimazawa
PURPOSE: Dipeptidyl peptidase-4 (DPP-4) inhibitors are oral hypoglycemic drugs and are used for type II diabetes. Previous studies showed that DPP-4 expression is observed in several tumor types and DPP-4 inhibitors suppress the tumor progression on murine tumor models. In this study, we evaluated the role of DPP-4 and the antitumor effect of a DPP-4 inhibitor, linagliptin, on glioblastoma (GBM). METHODS: We analyzed DPP-4 expression in glioma patients by the public database...
April 9, 2024: Biochemical and Biophysical Research Communications
https://read.qxmd.com/read/38602409/retagliptin-as-add-on-therapy-to-metformin-in-chinese-patients-with-type-2-diabetes-inadequately-controlled-with-metformin-a-multicentre-randomized-double-blind-placebo-controlled-phase-3-trial
#22
JOURNAL ARTICLE
Lixin Guo, Fengsheng Tian, Li Liu, Mingwei Chen, Chengxia Jiang, Shuangqing Li, Cong Liu, Yawei Zhang, Jie Qin, Dongni Yu, Yicen Zong, Wei Dai
AIM: To evaluate the efficacy and safety of retagliptin in Chinese patients with type 2 diabetes (T2D) inadequately controlled with metformin. MATERIALS AND METHODS: This multicentre, phase 3 trial consisted of a 16-week, randomized, double-blind, placebo-controlled period, where patients with HbA1c levels between 7.5% and 11.0% were randomized to receive either once-daily (QD) retagliptin 100 mg (n = 87) or placebo (n = 87), both as an add-on to metformin...
April 11, 2024: Diabetes, Obesity & Metabolism
https://read.qxmd.com/read/38600275/comparison-of-incident-hypertension-between-sglt2-inhibitors-vs-dpp4-inhibitors
#23
JOURNAL ARTICLE
Yuta Suzuki, Hidehiro Kaneko, Akira Okada, Jin Komuro, Katsuhito Fujiu, Norifumi Takeda, Hiroyuki Morita, Junya Ako, Akira Nishiyama, Yuichiro Yano, Masaki Ieda, Koichi Node, Hideo Yasunaga, Issei Komuro
Although several randomized clinical trials have reported the potential benefit of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in reducing blood pressure (BP), whether SGLT2i can reduce incident hypertension is unknown. We analyzed individuals with diabetes who were newly prescribed SGLT2i or dipeptidyl peptidase 4 inhibitors (DPP4i) in a large-scale epidemiological database. The primary outcome was the incidence of hypertension. A propensity score matching algorithm was employed to compare the subsequent development of hypertension between the SGLT2i and DPP4i groups...
April 10, 2024: Hypertension Research: Official Journal of the Japanese Society of Hypertension
https://read.qxmd.com/read/38599885/the-association-between-sodium-glucose-cotransporter-2-inhibitors-vs-dipeptidyl-peptidase-4-inhibitors-and-renal-outcomes-in-people-discharged-from-hospital-with-type-2-diabetes-a-population-based-cohort-study
#24
JOURNAL ARTICLE
Kate E D Ziser, Stephen Wood, George S Q Tan, Jedidiah I Morton, Jonathan E Shaw, J Simon Bell, Jenni Ilomaki
BACKGROUND: We investigated the association between post-hospital discharge use of sodium glucose cotransporter-2 inhibitors (SGLT-2is) compared to dipeptidyl peptidase-4 inhibitors (DPP-4is) and the incidence of hospitalization for acute renal failure (ARF) and chronic kidney disease (CKD) in people with type 2 diabetes. METHODS: We conducted a retrospective cohort study using linked hospital and prescription data. Our cohort included people aged ≥30 years with type 2 diabetes discharged from a hospital in Victoria, Australia, from December 2013 to June 2018...
April 2024: Journal of Diabetes
https://read.qxmd.com/read/38598767/association-of-sodium-glucose-cotransporter-2-inhibitors-and-the-risk-of-retinal-vascular-occlusion-a-real-world-retrospective-cohort-study-in-taiwan
#25
JOURNAL ARTICLE
Tzu-Yi Lin, Eugene Yu-Chuan Kang, Shih-Chieh Shao, Edward Chia-Cheng Lai, Nan-Kai Wang, Sunir J Garg, Kuan-Jen Chen, Je-Ho Kang, Wei-Chi Wu, Chi-Chun Lai, Yih-Shiou Hwang
AIMS: Sodium-glucose cotransporter-2 inhibitors (SGLT2is) are proposed to alleviate the development of inflammatory eye diseases. However, the association between SGLT2i and retinal vascular occlusion remains unclear. Therefore, this study aims to explore the effects of SGLT2i on the incidence of retinal vascular occlusion. MATERIALS AND METHODS: This retrospective cohort study analysed electronic medical records data from the largest multi-institutional database in Taiwan...
February 2024: Diabetes/metabolism Research and Reviews
https://read.qxmd.com/read/38598345/pharmacological-expansion-of-type-2-alveolar-epithelial-cells-promotes-regenerative-lower-airway-repair
#26
JOURNAL ARTICLE
Sida Shao, Nan Zhang, Gregory P Specht, Shaochen You, Lirui Song, Qiangwei Fu, David Huang, Hengyao You, Jian Shu, Alain Domissy, Shuangwei Li, Van Nguyen-Tran, Sean B Joseph, Arnab K Chatterjee, Jeffrey Jian Chen, Peter G Schultz, Michael J Bollong
Type 2 alveolar epithelial cells (AEC2s) are stem cells in the adult lung that contribute to lower airway repair. Agents that promote the selective expansion of these cells might stimulate regeneration of the compromised alveolar epithelium, an etiology-defining event in several pulmonary diseases. From a high-content imaging screen of the drug repurposing library ReFRAME, we identified that dipeptidyl peptidase 4 (DPP4) inhibitors, widely used type 2 diabetes medications, selectively expand AEC2s and are broadly efficacious in several mouse models of lung damage...
April 16, 2024: Proceedings of the National Academy of Sciences of the United States of America
https://read.qxmd.com/read/38595293/nicotinamide-adenine-dinucleotide-treatment-confers-resistance-to-neonatal-ischemia-and-hypoxia-effects-on-neurobehavioral-phenotypes
#27
JOURNAL ARTICLE
Xiaowen Xu, Xinxin Wang, Li Zhang, Yiming Jin, Lili Li, Meifang Jin, Lianyong Li, Hong Ni
JOURNAL/nrgr/04.03/01300535-202412000-00031/figure1/v/2024-04-08T165401Z/r/image-tiff Neonatal hypoxic-ischemic brain injury is the main cause of hypoxic-ischemic encephalopathy and cerebral palsy. Currently, there are few effective clinical treatments for neonatal hypoxic-ischemic brain injury. Here, we investigated the neuroprotective and molecular mechanisms of exogenous nicotinamide adenine dinucleotide, which can protect against hypoxic injury in adulthood, in a mouse model of neonatal hypoxic-ischemic brain injury...
December 1, 2024: Neural Regeneration Research
https://read.qxmd.com/read/38593588/active-site-directed-probes-targeting-dipeptidyl-peptidases-8-and-9
#28
JOURNAL ARTICLE
Margarida Espadinha, Joni De Loose, Sam Corthaut, Sofie Thys, Yentl Van Rymenant, Emile Verhulst, Siham Benramdane, Nicolò Filippi, Koen Augustyns, Pieter Van Wielendaele, Isabel Pintelon, Ingrid De Meester, Pieter Van der Veken
Dipeptidyl peptidases (DPP) 8 and 9 are intracellular serine proteases that play key roles in various biological processes and recent findings highlight DPP8 and DPP9 as potential therapeutic targets for hematological and inflammasome-related diseases. Despite the substantial progress, the precise biological functions of these proteases remain elusive, and the lack of selective chemical tools hampers ongoing research. In this paper, we describe the synthesis and biochemical evaluation of the first active site-directed DPP8/9 probes which are derived from DPP8/9 inhibitors developed in-house...
April 3, 2024: European Journal of Medicinal Chemistry
https://read.qxmd.com/read/38589688/inhibition-of-usp7-enhances-cd8-t-cell-activity-in-liver-cancer-by-suppressing-prdm1-mediated-fgl1-upregulation
#29
JOURNAL ARTICLE
Lin-Lin Sun, Li-Na Zhao, Jiao Sun, Hong-Feng Yuan, Yu-Fei Wang, Chun-Yu Hou, Pan Lv, Hui-Hui Zhang, Guang Yang, Ning-Ning Zhang, Xiao-Dong Zhang, Wei Lu
Lymphocyte activation gene 3 (LAG3), an immune checkpoint molecule expressed on activated T cells, functions as a negative regulator of immune responses. Persistent antigen exposure in the tumor microenvironment results in sustained LAG3 expression on T cells, contributing to T cell dysfunction. Fibrinogen-like protein 1 (FGL1) has been identified as a major ligand of LAG3, and FGL1/LAG3 interaction forms a novel immune checkpoint pathway that results in tumor immune evasion. In addition, ubiquitin-specific peptidase 7 (USP7) plays a crucial role in cancer development...
April 8, 2024: Acta Pharmacologica Sinica
https://read.qxmd.com/read/38585268/-bmspp-is-a-virus-resistance-gene-in-bombyx-mori
#30
JOURNAL ARTICLE
Yu-Ting Feng, Chun-Yan Yang, Lin Wu, Yuan-Cheng Wang, Guan-Wang Shen, Ping Lin
INTRODUCTION: Signal peptide peptidase ( SPP ) is an intramembrane protease involved in a variety of biological processes, it participates in the processing of signal peptides after the release of the nascent protein to regulate the endoplasmic reticulum associated degradation (ERAD) pathway, binds misfolded membrane proteins, and aids in their clearance process. Additionally, it regulates normal immune surveillance and assists in the processing of viral proteins. Although SPP is essential for many viral infections, its role in silkworms remains unclear...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38581842/efficacy-and-safety-of-sitagliptin-with-basal-plus-insulin-regimen-versus-insulin-alone-in-non-critically-ill-hospitalized-patients-with-type-2-diabetes-sita-plus-hospital-trial
#31
JOURNAL ARTICLE
Abraham Edgar Gracia-Ramos, María Del Pilar Cruz-Dominguez, Eduardo Osiris Madrigal-Santillán, Raúl Rojas-Martínez, José Antonio Morales-González, Ángel Morales-González, Mónica Hernández-Espinoza, Joaquín Vargas-Peñafiel, María de Los Ángeles Tapia-González
AIMS: To compare the efficacy and safety of basal-plus (BP) insulin regimen with or without sitagliptin in non-critically ill patients with type 2 diabetes (T2D). METHODS: This open-label, randomized clinical trial included inpatients with a previous diagnosis of T2D and blood glucose (BG) between 180 and 400 mg/dL. Participants received basal and correctional insulin doses (BP regimen) either with or without sitagliptin. The primary outcome was the difference in the mean daily BG among the groups...
April 3, 2024: Journal of Diabetes and its Complications
https://read.qxmd.com/read/38581656/bidirectional-relation-between-dipeptidyl-peptidase-4-and-angiotensin-ii-type-i-receptor-signaling
#32
JOURNAL ARTICLE
Flavia L Martins, Joao Carlos Ribeiro-Silva, Ravi Nistala, Adriana C C Girardi
Cardiometabolic diseases are often associated with heightened levels of angiotensin II (Ang II), which accounts for the observed oxidative stress, inflammation, and fibrosis. Accumulating evidence indicates a parallel upregulation of dipeptidyl dipeptidase 4 (DPP4) activity in cardiometabolic diseases, with its inhibition shown to mitigate oxidative stress, inflammation, and fibrosis. These findings highlight an overlap between the pathophysiological mechanisms used by Ang II and DPP4. Recent evidence demonstrates that targeted inhibition of DPP4 prevents the rise in Ang II and its associated molecules in experimental models of cardiometabolic diseases...
April 1, 2024: American Journal of Physiology. Cell Physiology
https://read.qxmd.com/read/38579756/narrative-literature-review-of-antidiabetic-drugs-effect-on-hyperuricemia-elaborate-on-actual-data-and-mechanisms
#33
REVIEW
Zhenyu Liu, Huixi Kong, Baoyu Zhang
To optimize the treatment plan for patients with type 2 diabetes mellitus (T2DM) and hyperuricemia, this narrative literature review summarizes the effect of antidiabetic drugs on serum uric acid (SUA) levels using data from observational studies, prospective clinical trials, post-hoc analyses and meta-analyses. SUA is an independent risk factor for T2DM, and evidence has shown that patients with both gout and T2DM exhibit a mutually interdependent effect on higher incidences. We find that insulin and dipeptidyl peptidase 4 inhibitor (DPP-4i) except linagliptin could increase the SUA, and other drugs including metformin, thiazolidinediones (TZDs), glucagon-like peptide-1 receptor agonists (GLP-1 RAs), linagliptin, sodium-glucose cotransporter 2 inhibitors (SGLT2i) and α-glucosidase inhibitors have a reduction effect on SUA...
April 1, 2024: Endocrine Connections
https://read.qxmd.com/read/38578395/summary-of-research-efficacy-and-safety-of-the-sglt2-inhibitor-empagliflozin-versus-placebo-and-the-dpp-4-inhibitor-linagliptin-versus-placebo-in-young-people-with-type-2-diabetes-dinamo-a-multicentre-randomised-double-blind-parallel-group-phase-3-trial
#34
JOURNAL ARTICLE
Lori M Laffel
The increasing occurrence of childhood overweight and obesity has been followed by a substantial increase in youth-onset type 2 diabetes (T2D). Pharmacological treatment options for youth-onset T2D remain limited, with a clear unmet need for additional oral agents. This summary of research reports on the efficacy and safety of empagliflozin and linagliptin on glycaemic control in children and adolescents aged 10-17 years with T2D in the randomised, double-blind, parallel group, phase 3 DINAMO trial. Empagliflozin provided a clinically relevant, statistically significant, and durable improvement in glycaemic control; however, linagliptin did not...
April 5, 2024: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://read.qxmd.com/read/38576104/identification-of-risk-factors-for-gliptin-associated-bullous-pemphigoid-among-diabetic-patients
#35
JOURNAL ARTICLE
Dana Shalmon, Efrat Bar-Ilan, Alon Peled, Shamir Geller, Jonathan Bar, Naama Schwartz, Eli Sprecher, Mor Pavlovsky
Drug-associated bullous pemphigoid has been shown to follow long-term gliptin (dipeptidyl-peptidase 4 inhibitors) intake. This study aimed at identifying risk factors for gliptin-associated bullous pemphigoid among patients with type 2 diabetes. A retrospective study was conducted in a tertiary centre among diabetic patients exposed to gliptins between the years 2008-2021. Data including demographics, comorbidities, medications, and laboratory results were collected using the MDClone platform. Seventy-six patients with type 2 diabetes treated with dipeptidyl-peptidase 4 inhibitors who subsequently developed bullous pemphigoid were compared with a cohort of 8,060 diabetic patients exposed to dipeptidyl-peptidase 4 inhibitors who did not develop bullous pemphigoid...
April 4, 2024: Acta Dermato-venereologica
https://read.qxmd.com/read/38570029/dipeptidyl-peptidase-4-mediated-fibronectin-processing-evokes-a-pro-fibrotic-extracellular-matrix
#36
JOURNAL ARTICLE
Karina A Zeyer, Olivier Bornert, Valentin Nelea, Xinyi Bao, Alexandre Leytens, Svetlana Sharoyan, Gerhard Sengle, Alvard Antonyan, Leena Bruckner-Tuderman, Jörn Dengjel, Dieter P Reinhardt, Alexander Nyström
Fibronectin serves as a platform to guide and facilitate deposition of collagen and fibrillin microfibrils. During development of fibrotic diseases, altered fibronectin deposition in the extracellular matrix (ECM) is generally an early event. Following this, dysregulated organization of fibrillins and fibrillar collagens occurs. Because fibronectin is an essential orchestrator of healthy ECM, perturbation of its ECM-organizational capacity may be involved in development of fibrosis. To investigate this, we employed recessive dystrophic epidermolysis bullosa (RDEB) as a disease model with progressive, severe dermal fibrosis...
April 1, 2024: Journal of Investigative Dermatology
https://read.qxmd.com/read/38569426/preventing-cxcl12-elevation-helps-to-reduce-acute-exacerbation-of-copd-in-individuals-co-existing-type-2-diabetes-a-bioinformatics-and-clinical-pharmacology-study
#37
JOURNAL ARTICLE
Hong Xue, Qianshun Chen, Xiuyan Lan, Hang Xu, Haitao Yang, Changjian Lin, Qing Xue, Baosong Xie
AIMS: To investigate the immunology shared mechanisms underlying chronic obstructive pulmonary disease (COPD) and type 2 diabetes mellitus (T2DM) and examine the impact of anti-diabetic drugs on acute exacerbation of COPD (AECOPD). METHODS: We analyzed GSE76925, GSE76894, GSE37768, and GSE25724 to identify differentially expressed genes. Hub-genes were identified through protein-protein interaction network analysis and evaluated by the receiver operating characteristic curve...
April 2, 2024: International Immunopharmacology
https://read.qxmd.com/read/38566233/regulatory-role-of-pi16-in-autoimmune-arthritis-and-intestinal-inflammation-implications-for-treg-cell-differentiation-and-function
#38
JOURNAL ARTICLE
Yuankai Sun, Shiyu Lin, Hui Wang, Lei Wang, Yulu Qiu, Feifei Zhang, Nannan Hao, Fang Wang, Wenfeng Tan
BACKGROUND: Regulatory T cells (Tregs) are crucial in maintaining immune homeostasis and preventing autoimmunity and inflammation. A proportion of Treg cells can lose Foxp3 expression and become unstable under inflammation conditions. The precise mechanisms underlying this phenomenon remain unclear. METHODS: The PI16 gene knockout mice (PI16fl/fl Foxp3Cre ) in Treg were constructed, and the genotypes were identified. The proportion and phenotypic differences of immune cells in 8-week-old mice were detected by cell counter and flow cytometry...
April 2, 2024: Journal of Translational Medicine
https://read.qxmd.com/read/38565942/usp26-promotes-colorectal-cancer-tumorigenesis-by-restraining-prkn-mediated-mitophagy
#39
JOURNAL ARTICLE
Qi Wu, Zhihong Wang, Siqi Chen, Xiaowei She, Shengyu Zhu, Pengcheng Li, Lang Liu, Chongchong Zhao, Kangdi Li, Anyi Liu, Changsheng Huang, Yaqi Chen, Fuqing Hu, Guihua Wang, Junbo Hu
Deubiquitinating enzymes (DUBs) are promising targets for cancer therapy because of their pivotal roles in various physiological and pathological processes. Among these, ubiquitin-specific peptidase 26 (USP26) is a protease with crucial regulatory functions. Our study sheds light on the upregulation of USP26 in colorectal cancer (CRC), in which its increased expression correlates with an unfavorable prognosis. Herein, we evidenced the role of USP26 in promoting CRC tumorigenesis in a parkin RBR E3 ubiquitin-protein ligase (PRKN) protein-dependent manner...
April 2, 2024: Oncogene
https://read.qxmd.com/read/38563864/dpp-4-inhibitors-sitagliptin-and-pf-00734-200-mitigate-dopaminergic-neurodegeneration-neuroinflammation-and-behavioral-impairment-in-the-rat-6-ohda-model-of-parkinson-s-disease
#40
JOURNAL ARTICLE
Seong-Jin Yu, Yun Wang, Hui Shen, Eun-Kyung Bae, Yazhou Li, Kumar Sambamurti, Michael A Tones, Margaret M Zaleska, Barry J Hoffer, Nigel H Greig
Epidemiological studies report an elevated risk of Parkinson's disease (PD) in patients with type 2 diabetes mellitus (T2DM) that is mitigated in those prescribed dipeptidyl peptidase 4 (DPP-4) inhibitors. With an objective to characterize clinically translatable doses of DPP-4 inhibitors (gliptins) in a well-characterized PD rodent model, sitagliptin, PF-00734,200 or vehicle were orally administered to rats initiated either 7-days before or 7-days after unilateral medial forebrain bundle 6-hydroxydopamine (6-OHDA) lesioning...
April 2, 2024: GeroScience
keyword
keyword
39554
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.